Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

M196R-TNFR2 and membrane TNFα down-regulate soluble TNFα-induced pro-metastatic functions in triple-negative breast cancer cells.

Cancer cell international·2026
Same author

Maternal postpartum depression risk differentially affects infant development across sociocultural groups.

BMC psychology·2026
Same author

Clinical Utility of an Ex Vivo Functional Test in Personalized Cancer Treatment.

Journal of personalized medicine·2026
Same author

Mental health care following stillbirth and termination of pregnancy: practice patterns and observed outcomes in a reproductive psychiatry center.

BMC pregnancy and childbirth·2026
Same author

Targeting bladder cancer: Potent anti-cancer effects of cannabichromene and delta-9-tetrahydrocannabinol-rich <i>Cannabis sativa</i> strains.

Asian journal of urology·2025
Same author

Perinatal depression during armed conflict in Israel: Mental health risks and challenges, a cross-sectional study.

Psychiatry research·2025

Related Experiment Video

Updated: Jun 13, 2025

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells
09:32

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells

Published on: February 27, 2020

8.8K

Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation.

Rakefet Ben-Yishay1, Opher Globus1, Nora Balint-Lahat2

  • 1Oncology Institute, Sheba Medical Center, Ramat Gan 5262000, Israel.

Cells
|September 14, 2024
PubMed
Summary

This study shows that combining PPARγ agonists and MEK inhibitors can successfully differentiate invasive breast cancer cells into adipocytes, offering a new therapeutic strategy for aggressive breast cancer subtypes.

Keywords:
EMTMEK inhibitorPPARγ agonistadipogenesisbreast cancerdifferentiation therapythiazolidinediones

More Related Videos

Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.8K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

39

Related Experiment Videos

Last Updated: Jun 13, 2025

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells
09:32

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells

Published on: February 27, 2020

8.8K
Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.8K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

39

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Epithelial-to-mesenchymal transition (EMT) drives breast cancer progression and drug resistance.
  • Dedifferentiated cancer cells exhibit plasticity, contributing to aggressive phenotypes.
  • Targeting cancer cell plasticity offers a novel therapeutic avenue.

Purpose of the Study:

  • To investigate a trans-differentiation therapeutic approach for invasive breast cancer cells.
  • To evaluate the efficacy of PPARγ agonists and MEK inhibitors in inducing cancer cell differentiation.
  • To explore combination therapies for overcoming drug resistance in aggressive breast cancer.

Main Methods:

  • Utilized murine breast cancer cells and patient-derived metastasis ex vivo cultures.
  • Administered PPARγ agonists (Rosiglitazone, Pioglitazone) and MEK inhibitors (Cobimetinib).
  • Assessed adipogenesis markers: PPARγ and C/EBPα upregulation, cytoskeleton rearrangement, lipid droplet accumulation.

Main Results:

  • PPARγ agonists and MEK inhibitors induced cancer cell trans-differentiation into adipocytes.
  • Rosiglitazone and Pioglitazone promoted adipogenesis, confirmed by molecular and morphological changes.
  • Cobimetinib, in combination with TGFβ, showed significant pro-adipogenic effects.
  • Synergistic PPARγ upregulation observed with Pioglitazone and Cobimetinib in triple-negative breast cancer cells.

Conclusions:

  • The combination of PPARγ agonists and MEK inhibitors represents a promising therapeutic strategy for aggressive breast cancer.
  • Targeting cancer cell plasticity and dedifferentiation can overcome drug resistance.
  • Differentiation therapy holds potential for treating invasive and metastatic breast cancer subtypes.